Evidence map›Paper›PMID 25919383›Full record

ArticleThe Journal of nervous and mental disease2015

North American Prodrome Longitudinal Study (NAPLS 2): The Prodromal Symptoms.

Jean Addington, Lu Liu, Lisa Buchy, Kristin S Cadenhead, Tyrone D Cannon, Barbara A Cornblatt, Diana O Perkins, Larry J Seidman, Ming T Tsuang, Elaine F Walker and 4 more

Registry-linked trialAbstract readConsensus Statement
In one paragraph

Article in The Journal of nervous and mental disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03932136 (Decreasing Risk of Psychosis by Sulforaphane), which is not on this map. Cited by 147 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
147citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03932136 phase3active not recruitingnot on this mapstarted 2019, after this paper: background citation

Decreasing Risk of Psychosis by Sulforaphane: Study Protocol for a Randomized, Double-blind, Placebo-controlled, Clinical Multicenter Trial (DROPS Trial)

TypeinterventionalSponsorShanghai Jiao Tong University School of MedicineRan2019 to 2026Enrolled300ConditionsClinical High Risk Syndrome of PsychosisArmsSulforaphane, Placebo
3 · Its place in the literature

Who cites it

147 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

87 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jean Addington*Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada; †Department of Psychiatry, UCSD, La Jolla, CA; ‡Department of Psychology, Yale University, New Haven, CT; §Department of Psychiatry, Zucker Hillside Hospital, Long Island, NY; ∥Department of Psychiatry, University of North Carolina, Chapel Hill, NC; ¶Department of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center and Massachusetts General Hospital, Boston, MA; #Departments of Psychology and Psychiatry, Emory University, Atlanta, GA; **Department of Psychiatry, Yale University, New Haven, CT; ††Departments of Psychiatry and Biobehavioral Sciences and Psychology, UCLA, Los Angeles; and ‡‡Department of Psychiatry, UCSF, and SFVA Medical Center, San Francisco, CA.
Lu Liu
Lisa Buchy
Kristin S Cadenhead
Tyrone D Cannon
Barbara A Cornblatt
Diana O Perkins
Larry J Seidman
Ming T Tsuang
Elaine F Walker
Scott W Woods
Carrie E Bearden
Daniel H Mathalon
Thomas H McGlashan

Funding

STRESS AND EMOTIONAL REACTIVITYP50MH066286 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NUECHTERLEIN, KEITH H · 2003 to 2014
$18.6M
1/9 Predictors and Mechanisms of Conversion to PsychosisU01MH081902 · NIMH · YALE UNIVERSITY · PI CANNON, TYRONE D · 2008 to 2018
$12.4M
Vulnerability to Progression SchizophreniaP50MH080272 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WOO, TSUNGUNG · 2007 to 2011
$9.9M
5/9 Predictors and Mechanisms of Conversion to PsychosisU01MH082004 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PERKINS, DIANA O. · 2008 to 2018
$7.5M
Administrative Supplement Harmonization of At Risk Multisite Observational Networks for Youth(HARMONY)U01MH081928 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI STONE, WILLIAM SETH · 2008 to 2018
$7.1M
4/9-Predictors and Mechanisms of Conversion to PsychosisU01MH081857 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI CORNBLATT, BARBARA A. · 2008 to 2018
$6.2M
8/9 Predictors and Mechanisms of Conversion to PsychosisU01MH082022 · NIMH · YALE UNIVERSITY · PI WOODS, SCOTT W · 2008 to 2018
$6.0M
2/9 - Predictors and Mechanisms of Conversion to PsychosisU01MH081988 · NIMH · EMORY UNIVERSITY · PI WALKER, ELAINE FRAN · 2008 to 2018
$5.4M
6/9-Predictors and Mechanisms of Conversion to PsychosisU01MH081944 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CADENHEAD, KRISTIN S. · 2008 to 2018
$4.9M
"7/9" Predictors and Mechanisms of Conversion to PsychosisU01MH081984 · NIMH · UNIVERSITY OF CALGARY · PI ADDINGTON, JEAN M · 2008 to 2018
$4.2M
VULNERABILITY MARKERS IN PRODROMAL SCHIZOPHRENIAR01MH060720 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CADENHEAD, KRISTIN S. · 2000 to 2010
$4.0M
9/9-Predictors and Mechanisms of Conversion to PsychosisU01MH076989 · NIMH · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MATHALON, DANIEL H · 2014 to 2018
$3.9M
NIMH NIH HHS K24 MH076191NIMH NIH HHS K24 MH76191NIMH NIH HHS P50 MH066286NIMH NIH HHS P50MH066286NIMH NIH HHS P50 MH080272NIMH NIH HHS R01 MH060720NIMH NIH HHS R01 MH60720NIMH NIH HHS U01 MH076989NIMH NIH HHS U01 MH081857NIMH NIH HHS U01 MH081902NIMH NIH HHS U01MH081902NIMH NIH HHS U01 MH081928NIMH NIH HHS U01 MH081944NIMH NIH HHS U01 MH081984NIMH NIH HHS U01MH081984NIMH NIH HHS U01 MH081988NIMH NIH HHS U01MH081988NIMH NIH HHS U01 MH082004NIMH NIH HHS U01MH082004NIMH NIH HHS U01 MH082022NIMH NIH HHS U01MH082022NIMH NIH HHS UO1MH081857-05
6 · The paper itself

Abstract

In studies describing the long-term follow-up up of youth at clinical high risk (CHR) of psychosis, little attention has been given to details of specific prodromal symptoms. In this paper, we describe the prodromal symptoms of 764 CHR participants recruited in the multi-site North American Prodrome Longitudinal Study (NAPLS). Symptoms were rated on the Scale of Prodromal Symptoms (SOPS) at baseline and 6-, 12-, 18-, and 24-month follow-ups. Clinical outcome at the 2-year assessment was categorized as psychotic, prodromal progression, symptomatic or in remission. Most of the CHR sample (92%) met criteria for the attenuated positive symptoms syndrome (APSS). Significant improvements in SOPS symptoms were observed over time. Unusual thought content, disorganized communication, and overall ratings on disorganized symptoms differentiated those who transitioned to psychosis from the other clinical outcome groups. Suspiciousness and total positive symptoms differentiated those in remission from the other clinical outcome groups.

Indexed as

Early DiagnosisProdromal SymptomsSchizophrenic PsychologyAdolescentAdultAlgorithmsCase-Control StudiesDiagnostic and Statistical Manual of Mental DisordersDisease ProgressionFemaleHumansLongitudinal StudiesMaleNorth AmericaPsychiatric Status Rating ScalesPsychometrics

Identifiers

PMID25919383
PMCPMC4417745

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.